Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verona: venetoclax plus azacitidine in newly diagnosed higher-risk myelodysplastic syndrome
jRCT2031200130Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Venetoclax + Azacitidine with Placebo + Azacitidine (2 arms). Primary endpoint: Overall survival. Started Oct 2020; status: active, not recruiting.
02
Drugs
venetoclaxazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCT2031200130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200130.